A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Meropenem

Penem Antibacterial class · 8 generic manufacturers · 19 ANDAs filed at FDA.

First FDA approval2011-10-14
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$26.3M in CY2024 Part D spend144K claims · 48K beneficiaries · 329 plans surveyed

Lowest NADAC
$5.84/unit
13 NDCs benchmarked, lowest of all strengths.
Average NADAC
$5.84
Across all dosage forms in distribution.
Highest NADAC
$5.84
Range is tight.
Plans with PA
40 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Meropenem used for?

Meropenem is a Penem Antibacterial medication tracked in Medicare Part D.

Is there a generic for Meropenem?

Yes. 19 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Meropenem?

Across 329 Part D plans, Meropenem averages $5.84/unit (NADAC). Lowest available: $5.84/unit. Highest in distribution: $5.84/unit.

Is Meropenem on the FDA shortage list?

No. Meropenem is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Penem Antibacterial3 alternatives in D1
01
Ertapenem
Brand: ERTAPENEM
$26.83Lowest NADAC
5Generic mfrs
$108.0MCY24 Part D spend
Compare →
02
Imipenem and Cilastatin
Brand: Imipenem and Cilastatin
Lowest NADAC
2Generic mfrs
CY24 Part D spend
Compare →
03
Meropenem-Vaborbactam
Brand: VABOMERE
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (13 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.